Novai
Alex Wilson has a diverse range of work experience spanning various industries. Alex is currently working at Novai, where they hold the position of Director of Corporate Development & Quality. Prior to this role, they were the Head of Business Development at Novai. Before joining Novai, Alex founded and served as the Principal of AWSQUARED LTD. Alex also held the position of Chief Operating Officer at Neuro-Bio Limited.
Alex's previous experience includes serving as the Managing Director of Apta Biosciences Pte Ltd, Principal Consultant at Biomedical Consulting, and Program Director at the Institute of Molecular & Cell Biology, A*STAR. Alex has also held leadership positions at Maccine Pte Ltd, including Chief Executive Officer, Chief Operating Officer, Chief Scientific Officer, and Head of Experimental Pharmacology.
Early in their career, Alex was an Investigator at GlaxoSmithKline, where they led a team of scientists in developing pharmacodynamic models in the Neuroscience disease areas. Alex also conducted post-doctoral research at Hammersmith Hospital.
Alex Wilson completed a Bachelor of Science (BSc) in Biomedical Science with a focus on Pharmacology and Toxicology at the University of Bradford from 1989 to 1993, achieving First Class honors. Following that, from 1993 to 1996, Alex pursued a PhD in Psychopharmacology at the same institution. Finally, from 2012 to 2016, Alex attended The University of Chicago Booth School of Business, where they earned a Master of Business Administration (M.B.A.). No field of study was specified for the MBA program.
This person is not in any teams
Novai
Novai is a British biotechnology start-up, commercialising DARC Technology, an exploratory retinal biomarker for use in Age-related Macular Degeneration (AMD) & glaucoma clinical studies. DARC combines an innovative patented biologic with a state-of-the-art AI algorithm and uses standard imaging equipment to identify cellular level diseaseactivity. DARC Technology can be used to measure the impact of current and future therapeutics and interventions by assessment of disease activity whilst identifying non-responders to existing and new interventions, resulting in the avoidance of costly, ineffective or un-required medical management. DARC helps to stratify patients in clinical trials, resulting in the creation of enriched patient cohorts, consisting of those at highest risk of rapid disease progression.DARC has been developed by Professor M Francesca Cordeiro at University College London through Wellcome Trust funding and is now approved as an exploratory biomarker by the FDA & MHRA. Following further analysis of Phase II data, several other indications may follow, including Multiple Sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Diabetes Mellitus and Cancer.